ViroNovative BV, established in 2002, is dedicated to providing a complete solution to human Metapneumovirus (hMPV), a virus discovered in 2001 at the Department of Viroscience, Erasmus MC. To this end, ViroNovative is co-developing diagnostics, vaccines, antibodies and antivirals for the detection, prevention and treatment of hMPV infection. With a strong network of industrial partners (to date 20 licenses on the hMPV patents are active) we generate new products and economic value.
ViroNovative and its founders have a strong but arms length relation with Viroclinics Biosciences BV and closely cooperate with the Department of Viroscience ErasmusMC Rotterdam thereby unlocking the potential of almost 200 academically involved virologists and service- diagnostics- providers.
ViroNovative BV, a limited liability company, is a spin out company and full subsidiary formed over ten years ago under the active incubator policy of Erasmus MC Holding BV. Erasmus MC is one of the largest European academic hospitals (over fifiteen thousand employees) and consisitently ranks among the top Medical Schools and Research centers in Europe.